{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T01:47:27Z","timestamp":1791683247754,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cardfail.2026.09.017","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:49:38Z","timestamp":1791679778000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous Vutrisiran Reduces Cardiovascular Events and Hospitalizations in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B One-Year Open Label Extension"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-2151","authenticated-orcid":false,"given":"Sarah A.M.","family":"Cuddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan M.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8335-735X","authenticated-orcid":false,"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-6582","authenticated-orcid":false,"given":"Olivier","family":"Lairez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-6094","authenticated-orcid":false,"given":"Caroline","family":"Morbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9687-9475","authenticated-orcid":false,"given":"Farooq H.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1319-0563","authenticated-orcid":false,"given":"Benjamin W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-7221","authenticated-orcid":false,"given":"Alisa R.","family":"Kosheleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-1472","authenticated-orcid":false,"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2026.09.017_bib0001","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","article-title":"Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness","volume":"27","author":"Nativi-Nicolau","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0003","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0004","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5334\/gh.1262","article-title":"World Heart Federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM)","volume":"18","author":"Brito","year":"2023","journal-title":"Glob Heart"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0006","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/ehf2.13913","article-title":"Healthcare resource use of patients with transthyretin amyloid cardiomyopathy","volume":"9","author":"Lauppe","year":"2022","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.cardfail.2026.09.017_bib0007","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0008","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cardfail.2026.09.017_bib0009","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40262-026-01651-3","article-title":"Vutrisiran-mediated knockdown of transthyretin in patients with ATTR amyloidosis","volume":"65","author":"Fontana","year":"2026","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0010","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2025.04.008","article-title":"Vutrisiran improves survival and reduces cardiovascular events in ATTR amyloid cardiomyopathy: HELIOS-B","volume":"85","author":"Witteles","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.cardfail.2026.09.017_bib0011","series-title":"European Society of Cardiology (ESC)","article-title":"HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","author":"Garcia-Pavia","year":"2025"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0012","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jacc.2025.04.055","article-title":"Impact of vutrisiran on cardiac biomarkers in patients with transthyretin amyloidosis with cardiomyopathy from HELIOS-B","volume":"86","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0013","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2024.15219","article-title":"Surrogate end points in trials\u2014SPIRIT and CONSORT extensions","volume":"332","author":"Taylor","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2023.111242","article-title":"Surrogate endpoints: a key concept in clinical epidemiology","volume":"167","author":"Christensen","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0015","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1001\/jama.2020.1176","article-title":"When can intermediate outcomes be used as surrogate outcomes?","volume":"323","author":"DeMets","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0016","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jacc.2025.09.1512","article-title":"Timing of mortality benefit in outcomes trials in transthyretin amyloidosis","volume":"87","author":"Claggett","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0017","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/jamacardio.2026.0819","article-title":"Long-term durability of acoramidis efficacy in transthyretin amyloid cardiomyopathy: open-label extension of the ATTRibute-CM randomized clinical trial","volume":"11","author":"Soman","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0018","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ejhf.2974","article-title":"Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms","volume":"25","author":"Elliott","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0019","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1253\/circrep.CR-25-0031","article-title":"Real-world clinical impact of tafamidis on transthyretin amyloid cardiomyopathy - a decade of experience from a community-based hospital (2015\u20132024)","volume":"7","author":"Kubota","year":"2025","journal-title":"Circulation Reports"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0020","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0021","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.jacc.2025.03.477","article-title":"Impact of heart failure severity on vutrisiran efficacy in transthyretin amyloidosis with cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0022","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cardfail.2025.11.129","article-title":"Efficacy of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy by baseline health status and quality of life","volume":"32","author":"Sheikh","year":"2026","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0023","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10741-024-10444-4","article-title":"Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis","volume":"30","author":"Girard","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfag118","article-title":"ATTR: The forgotten kidney amyloidosis","author":"Soler","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0025","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.3390\/jcm14134682","article-title":"Prevalence of autonomic dysfunction and correlation with markers of disease severity in cardiac amyloidosis","volume":"14","author":"Poledniczek","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0026","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jns.12589","article-title":"Ophthalmological involvement in wild-type transthyretin amyloidosis: A multimodal imaging study","volume":"28","author":"Frizziero","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2026.2695367","article-title":"Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study","author":"Urey","year":"2026","journal-title":"Amyloid"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0028","doi-asserted-by":"crossref","first-page":"xuag088","DOI":"10.1093\/ejhf\/xuag088","article-title":"Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study","author":"Hamatani","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0029","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.cardfail.2026.02.049","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy and renal impairment: analyses from HELIOS-B","volume":"32","author":"Sheikh","year":"2026","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0030","series-title":"Heart Failure2026","article-title":"Influence of disease modifying therapy on the effectiveness of vutrisiran in transthyretin cardiac amyloidosis","author":"Abovich","year":"2026"},{"key":"10.1016\/j.cardfail.2026.09.017_bib0031","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2608510","article-title":"Eplontersen for transthyretin amyloid cardiomyopathy","author":"Fontana","year":"2026","journal-title":"N Engl J Med."}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426005786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426005786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:49:42Z","timestamp":1791679782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916426005786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":31,"alternative-id":["S1071916426005786"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.09.017","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous Vutrisiran Reduces Cardiovascular Events and Hospitalizations in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B One-Year Open Label Extension","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}